Top

Published in:

01-02-2018 | Laboratory Investigation

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma

Authors: Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae-Yong Kim, Hye Seung Lee, Gheeyoung Choe

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

The aim of this study was to determine the clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in glioblastoma (GBM). In a retrospective cohort of 115 consecutive patients with GBM, PD-L1 expression was determined using immunohistochemistry (IHC). Membranous and fibrillary PD-L1 staining of any intensity in > 5% neoplastic cells and tumour infiltrating immune cells (TIIs) was considered positive staining. In addition, isocitrate dehydrogenase-1 (IDH-1) (R132H) expression and cluster of differentiation 3 (CD3)-positive T-cell infiltration were investigated using IHC. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation assay and fluorescence in situ hybridization (FISH) for the assessment of 1p/19q deletion were performed. Expression of PD-L1 in tumour cells and TIIs was found in 37 (32.2%) and 6 (5.2%) patients, respectively. Kaplan–Meier analysis indicated that PD-L1 expression in tumour cells was significantly associated with poor overall survival (OS) (P = 0.017), though multivariate Cox analysis did not confirm this association (hazard ratio 1.204; P = 0.615). PD-L1 expression in TIIs did not correlate with the patient prognosis (P = 0.545). In addition, MGMT methylation and IDH-1 (R132H) expression were associated with a better prognosis (P < 0.001 and P = 0.024, respectively). The expression of PD-L1 was associated with CD3-positive T-cell infiltration (P < 0.001), and IDH-1 wild type status (P = 0.008). A deeper insight into PD-L1 expression could help to ensure the success of future immunotherapy in GBM. Our study suggested that PD-L1 target therapy might be beneficial for PD-L1-expressing GBM patients with a poor prognosis.

Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19(5):1021–1034. https://doi.org/10.1158/1078-0432.CCR-12-2063 CrossRefPubMedPubMedCentral

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856. https://doi.org/10.1158/1535-7163.MCT-14-0983 CrossRefPubMed

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105 CrossRefPubMedPubMedCentral

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 CrossRefPubMed

Asaoka Y, Ijichi H, Koike K (2015) PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 373(20):1979. https://doi.org/10.1056/NEJMc1510353#SA1 CrossRefPubMed

Sonpavde G (2017) PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma. New Engl J Med 376(11):1073–1074. https://doi.org/10.1056/NEJMe1701182 CrossRefPubMed

He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13110. https://doi.org/10.1038/srep13110 CrossRefPubMedPubMedCentral

Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643. https://doi.org/10.1182/blood-2007-11-123141 CrossRefPubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 (10):987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

10.

Dunn-Pirio AM, Vlahovic G (2017) Immunotherapy approaches in the treatment of malignant brain tumors. Cancer 123(5):734–750. https://doi.org/10.1002/cncr.30371 CrossRefPubMed

11.

Tivnan A, Heilinger T, Lavelle EC, Prehn JH (2017) Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol 131(1):1–9. https://doi.org/10.1007/s11060-016-2299-2 CrossRefPubMed

12.

Reardon DA, Brandes AO,AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, Vlahovic G, Sampson J (2017) Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkMate 143. Paper presented at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, Abstract (OS10.3)

13.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920. https://doi.org/10.1016/s0140-6736(16)00561-4 CrossRefPubMedPubMedCentral

14.

Wu P, Wu D, Li L, Chai Y, Huang J (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE 10(6):e0131403. https://doi.org/10.1371/journal.pone.0131403 CrossRefPubMedPubMedCentral

15.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neur-Oncology 17(8):1064–1075. https://doi.org/10.1093/neuonc/nou307 CrossRefPubMed

16.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB (2016) PD-L1 expression and prognostic impact in glioblastoma. Neur-Oncology 18(2):195–205. https://doi.org/10.1093/neuonc/nov172 CrossRefPubMed

17.

Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX (2016) Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 7(8):8944–8955. https://doi.org/10.18632/oncotarget.6884 CrossRefPubMedPubMedCentral

18.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

19.

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 343(19):1350–1354. https://doi.org/10.1056/NEJM200011093431901 CrossRefPubMed

20.

Ambros PF, Ambros IM, Siop Europe Neuroblastoma Pathology B, Bone Marrow G (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37(6):492–504CrossRefPubMed

21.

Babu R, Sharma R, Karikari IO, Owens TR, Friedman AH, Adamson C (2013) Outcome and prognostic factors in adult cerebellar glioblastoma. J Clin Neurosci 20(8):1117–1121. https://doi.org/10.1016/j.jocn.2012.12.006 CrossRefPubMed

22.

Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445–1453. https://doi.org/10.2353/ajpath.2007.070011 CrossRefPubMedPubMedCentral

23.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. New Engl J Med 360(8):765–773. https://doi.org/10.1056/NEJMoa0808710 CrossRefPubMedPubMedCentral

24.

Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28(2):115–123. https://doi.org/10.1007/s10014-011-0023-7 CrossRefPubMed

25.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neur-Oncology 12(2):116–121. https://doi.org/10.1093/neuonc/nop020 CrossRefPubMed

26.

Barker CF, Billingham RE (1977) Immunologically privileged sites. Adv Immunol 25:1–54PubMed

27.

Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81(3):374–389. https://doi.org/10.1002/jnr.20488 CrossRefPubMed

28.

Aloisi F (2001) Immune function of microglia. Glia 36(2):165–179CrossRefPubMed

29.

Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19(1):20–27. https://doi.org/10.1038/nn.4185 CrossRefPubMedPubMedCentral

30.

Dubois LG, Campanati L, Righy C, D’Andrea-Meira I, Spohr TC, Porto-Carreiro I, Pereira CM, Balca-Silva J, Kahn SA, DosSantos MF, Oliveira Mde A, Ximenes-da-Silva A, Lopes MC, Faveret E, Gasparetto EL, Moura-Neto V (2014) Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci 8:418. https://doi.org/10.3389/fncel.2014.00418 CrossRefPubMedPubMedCentral

31.

Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ, Sodek J (2011) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132(1):39–48. https://doi.org/10.1111/j.1365-2567.2010.03335.x CrossRefPubMedPubMedCentral

32.

Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL (2005) Role of microglia in the central nervous system’s immune response. Neurol Res 27(7):685–691. https://doi.org/10.1179/016164105X49463 PubMed

33.

Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW (2005) Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 85(3):328–341. https://doi.org/10.1038/labinvest.3700233 CrossRefPubMed

34.

Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A (1992) Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148(5):1404–1410PubMed

35.

Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet N, Walker PR, Dietrich PY (2005) B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16(10):1081–1085CrossRefPubMed

36.

Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neur-Oncology 11(4):394–402. https://doi.org/10.1215/15228517-2008-104 CrossRefPubMedPubMedCentral

37.

Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253. https://doi.org/10.1111/pcmr.12340 CrossRefPubMed

38.

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvee S, Washetine K, Mouroux J, Venissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153. https://doi.org/10.1093/annonc/mdv489 CrossRefPubMed

39.

Lee KS, Kwak Y, Ahn S, Shin E, Oh HK, Kim DW, Kang SB, Choe G, Kim WH, Lee HS (2017) Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother 66(7):927–939. https://doi.org/10.1007/s00262-017-1999-6 CrossRefPubMed

40.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed

41.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12(2):208–222. https://doi.org/10.1016/j.jtho.2016.11.2228 CrossRefPubMed

42.

Krabbe LM, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V (2017) Prognostic Value of PD-1 and PD-L1 expression in patients with high-grade upper tract urothelial carcinoma. J Urol. https://doi.org/10.1016/j.juro.2017.06.086

43.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II (2017) A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 3(8):1051–1058. https://doi.org/10.1001/jamaoncol.2017.0013 CrossRefPubMedPubMedCentral

44.

Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023–5039. https://doi.org/10.2147/OTT.S105862 CrossRefPubMedPubMedCentral

45.

Han J, Hong Y, Lee YS (2017) PD-l1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med 51(1):40–48. https://doi.org/10.4132/jptm.2016.08.31 CrossRefPubMed

46.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940. https://doi.org/10.1093/annonc/mdu242 CrossRefPubMed

47.

Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M (2016) PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 29(9):1104–1112. https://doi.org/10.1038/modpathol.2016.95 CrossRefPubMed

48.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wohrer A, Marosi C, Hegi ME, Preusser M (2017) Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. https://doi.org/10.1093/neuonc/nox054

49.

Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, Gabelein A, Pfeifer D, Carro MS, Weyerbrock A, Prinz M, Schnell O (2017) Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget 8(26):42214–42225. https://doi.org/10.18632/oncotarget.15031 CrossRefPubMedPubMedCentral

50.

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H (2017) Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 127(4):1425–1437. https://doi.org/10.1172/JCI90644 CrossRefPubMedPubMedCentral

Title: Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
Authors: Kyu Sang Lee
Kyoungyul Lee
Sumi Yun
Seyoung Moon
Yujun Park
Jung Ho Han
Chae-Yong Kim
Hye Seung Lee
Gheeyoung Choe
Publication date: 01-02-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2675-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas

Bioinformatic analysis of gene expression and methylation regulation in glioblastoma

P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma

Characteristics of cerebellar glioblastomas in adults

Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model